Head-to-head · WeighScore
BeyondMD vs PepHaūs
The verdict
PepHaūs takes it — 82.7/100 to 66.8/100.
PepHaūs grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Verified and nationwide, but priced in the upper-mid band ($152/$246).
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | BeyondMD | PepHaūs |
|---|---|---|
| WeighScore | 66.8/100 | 82.7/100 |
| Grade | C | B− |
| Site position | #199 | #27 |
| Semaglutide | $139/mo (starting dose, compounded) | $152/mo |
| Tirzepatide | $209/mo (starting dose, compounded) | $246/mo |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Site position #199 · C
Strengths
- Aggressively low monthly pricing
- Both semaglutide and tirzepatide available
- Compounded GLP-1 access
Where it loses points
- Limited public information on program details
Site position #27 · B−
Strengths
- LegitScript-verified, all 50 states
- Both molecules
- Transparent listed pricing
Where it loses points
- Upper-mid pricing ($152/$246)
- Injection-only
- Monitoring detail limited
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). CoreAge Rx advertises flat dose pricing for compounded injections, with no membership fee; its consultation-fee and refund deadlines deserve a close read before paying.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.